Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin and Atorvastatin in Postmenopausal CAD
NCT03943459Phase 3Unknown
- Start
- Aug 2019
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (3 arms). Primary endpoints: Serum Concentration of Sirtuin-1 at 60 days and Soluble Receptor for Advanced Glycation End Products at 60 days. Status: unknown.
Beyond the preview
Go deeper on NCT03943459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943459.